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CytokineArthritic pain is a serious health problem that affects a large number of patients. Toll-like receptors (TLRs)
activation within the joints has been implicated in pathophysiology of arthritis. However, their role in the
genesis of arthritic pain needs to be demonstrated. In the present study, it was addressed the participation
of TLR2 and TLR4 and their adaptor molecule MyD88 in the genesis of joint hypernociception (a decrease
in the nociceptive threshold) during zymosan-induced arthritis. Zymosan injected in the tibio-tarsal joint
induced mechanical hypernociception in C57BL/6 wild type mice that was reduced in TLR2 and MyD88
null mice. On the other hand, zymosan-induced hypernociception was similar in C3H/HePas and C3H/HeJ
mice (TLR4 mutant mice). Zymosan-induced joint hypernociception was also reduced in TNFR1 null mice
and in mice treated with IL-1 receptor antagonist or with an antagonist of CXCR1/2. Moreover, the joint pro-
duction of TNF-α, IL-1β and CXCL1/KC by zymosan was dependent on TLR2/MyD88 signaling. Investigating
the mechanisms by which TNF-α, IL-1β and CXCL1/KC mediate joint hypernociception, joint administration
of these cytokines produced mechanical hypernociception, and they act in an interdependent manner. In last
instance, their hypernociceptive effects were dependent on the production of hypernociceptive mediators,
prostaglandins and sympathetic amines. These results indicate that in zymosan-induced experimental arthri-
tis, TLR2/MyD88 is involved in the cascade of events of joint hypernociception through a mechanism depen-
dent on cytokines and chemokines production. Thus, TLR2/MyD88 signaling might be a target for the
development of novel drugs to control pain in arthritis.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Rheumatoid arthritis is an autoimmune disease of unknown etiol-
ogy associated with chronic inﬂammation of joints and joint pain.
Movement-induced joint hyperalgesia is a serious burden to patients
presenting inﬂammatory arthropathies. This clinical state (hyperalge-
sia) is better deﬁned as hypernociception in experimental models
because the majority of experimental nociceptive tests do not differ-
entiate hyperalgesia from allodynia. Recently, we developed an
experimental model of inﬂammatory joint hypernociception in
mice, in which the dorsal ﬂexion of inﬂamed tibio-tarsal joint elicits
hypernociception. This method allows direct quantiﬁcation of this
inﬂammatory symptom (Guerrero et al., 2006). However, the mecha-
nisms of initiation and perpetuation of the inﬂammatory pain in
rheumatoid arthritis are not completely understood.x: +55 16 3633 0021.
a), shferrei@fmrp.usp.br
vier OA license.Toll-like receptors (TLRs) are a family of pattern recognition
receptors that are involved in the recognition of conserved
pathogen-associated molecular patterns (Akira, 2006). They are con-
served proteins with an extracellular leucine-rich domain and an in-
tracellular Toll/IL-1 like receptor (TIR) domain. To date, 11 members
of the TLR family have been-identiﬁed in humans and 13 in mice,
being TLR4 the ﬁrst described in mammals (Akira and Takeda, 2004;
Beutler, 2004). Besides to recognize pathogens-associated molecules,
there is a novel concept in which endogenous substance could also
activates TLRs. For instance, TLR4 has been involved in the recogni-
tion of hsp60, ﬁbronectin, heme and multiple host protein (Akira,
2006; Andreakos et al., 2005). Among TLRs, TLR2 and TLR4 have
been found highly expressed in synovial tissues of rheumatoid arthri-
tis patients (Radstake et al., 2005). Functionally, genetic or pharmaco-
logic blockade of TLR2 or TLR4 results in the amelioration of arthritis
in different experimental models (Seibl et al., 2003; Radstake et al.,
2005; Joosten et al., 2003).
The intracellular signaling pathways activated by TLR2 and TLR4
involve the selective recruitment of adapter proteins of which
MyD88 is better known. These intracellular cascades lead to the
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trigger the production of inﬂammatory mediators that might contrib-
utes to joint inﬂammation (Akira and Takeda, 2004). Indeed, it is gen-
erally accepted that proinﬂammatory cytokines (TNF-α and IL-1β)
and chemokines (CXCL8/IL-8 and CXCL1/KC) play an important role
in the pathogenesis of rheumatoid arthritis (Pierer et al., 2004;
Radstake et al., 2005; Haas et al., 2005). Although, a great body of ev-
idence point out these cytokines as important to genesis of inﬂamma-
tory pain (Cunha et al., 1992, 2005; Verri et al., 2008), their role in the
generation of arthritic nociception was not fully addressed. Taking in
account these evidences, in the present study, we investigated the
role of TLR2, TLR4 and their adapter molecule, MyD88 in the cascade
of events involved in the genesis of joint hypernociception during
zymosan-induced arthritis. We focused mainly in the role of TLRs
triggering cytokine-dependent mechanisms.
2. Materials and methods
2.1. Animals
All experiments were carried out on male C57BL/6 wild type (WT)
mice, TNFR1 null mice(−/−), TRL2−/−, and MyD88−/− (20–25 g). To
investigate the involvement of TLR4, C3H/HeJ mice carrying a
dominant-negative mutation in the cytoplasmic domain of TLR4
were used and their littermates C3H/HePas. TNFR1−/−, C3H/HePas
and C3H/HeJ mice were obtained from Jackson Laboratories (Bar Har-
bor, ME, USA). Myd88−/− and TLR2−/− were generated by S. Akira
(Osaka University, Japan) and they were a gift to R.T. Gazzinelli.
TNFR1−/−, Myd88−/−, and TLR2−/− were backcrossed at least eight
generations into the C57BL/6 background. Mice were housed in the
animal care facility of the School of Medicine of Ribeirão Preto. Mice
were taken to the testing room at least 1 h before experiments and
were used once. All experiments were double blinded and conducted
in accordance with the guidelines of the National Institute of Health
on the welfare of experimental animals and with the approval of
the Ethics Committee of the Faculty of Medicine of Ribeirão Preto,
University of São Paulo.
2.2. Induction of tibio-tarsal joint inﬂammation
Joint inﬂammation was induced by administration of zymosan
(30 μg) (Guerrero et al., 2006), LPS (300 ng/5 μl), TNF-α (1–
1000 pg/5 μl), IL-1β (100–5000 pg/5 μl) and CXCL1/KC (1–100 ng/
5 μl) diluted in 5 μl of saline and injected into the right tibio-tarsal
joint of mice anesthetized with isoﬂurane (2%). The substances
were injected with a 29 G hypodermic needle inserted into the
joint. Control animals received an intra-articular injection of 5 μl ster-
ile saline.
2.3. Articular ﬂexion-elicited hypernociception in the inﬂamed joint:
assessment by a modiﬁed electronic pressure-meter test for mice
Experiments were performed as previously described by Guerrero
et al. (2006) which is a modiﬁcation of the test described earlier by
Cunha et al. (2004). In a quiet room, mice were placed in acrylic
cages (12×10×17 cm high) with a wire grid ﬂoor 15–30 min before
testing for environmental adaptation. Stimulations were performed
only when animals were quiet, without exploratory movements or
defecation and not resting on their paws. In these experiments, an
electronic pressure-meter was used. It consists of a hand-held force
transducer ﬁtted with a polypropylene tip (IITC Inc., Life Science In-
struments, Woodland Hills, CA, USA). An increasing perpendicular
force applied to the central area of the plantar surface induced the
ﬂexion of the tibio-tarsal joint. A tilted mirror below the grid provid-
ed a clear view of the animal's hind paw. In the electronic pressure-
meter test, the intensity of the stimulus was automatically recordedwhen the paw was withdrawn. The non-nociceptive tip probe area
size used to evaluate the movement-elicited hypernociception was
4.15 mm2. The ﬂexion-elicited withdrawal threshold is expressed in
grams (g).2.4. Cytokine and chemokine measurements (ELISA)
At indicated times after the inﬂammation stimuli injection, ani-
mals were killed, and the tibio-tarsal joint regions injected with zy-
mosan or saline were separated from the tibio-tarsal bone complex.
The tibio-tarsal joint samples were homogenized in 500 μl of the ap-
propriate buffer containing protease inhibitors, and TNF-α, IL-1β,
and KC levels were determined by ELISA (Cunha et al., 2007). The re-
sults are expressed as picograms of each cytokine or chemokine per
joint.2.5. Drugs and reagents
Murine recombinant TNF-α, IL-1β, and interleukin 1 receptor
antagonist (IL-1ra) were provided by the National Institute for
Biological Standards and Control (South Mimms, Herfordshire, UK);
recombinant murine CXCL1/KC was purchased from PeproTech
(Rocky Hill, NJ); indomethacin (non-selective cyclo-oxigenase inhib-
itor) was obtained from Prodome (Campinas, SP, Brazil); zymosan,
Lipopolysaccharide, (LPS) and guanethidine were obtained from
Sigma (St Louis, MO, USA); DF 2162 was obtained from laboratories
of Dompé pharma (L'Aquila, Italy).2.6. Statistical analysis
Results are presented as means±S.E.M. and are representative of
two separate experiments of 5 animals per group. Two-way analysis
of variance (ANOVA) was used to compare the groups and doses at
all times (curves) when the hypernociceptive responses were mea-
sured at different times after the stimulus injection. The analyzed fac-
tors were treatments, time and time versus treatment interaction.
When there was a signiﬁcant time versus treatment interaction,
one-way ANOVA followed by Bonferroni's t test was performed for
each time. Alternatively, when the hypernociceptive responses were
measured once after the stimulus injection, the differences between
responses were evaluated by one-way ANOVA followed by Bonferro-
ni's t test. Statistical differences were considered to be signiﬁcant at
Pb0.05.3. Results
3.1. Participation of TLR2/MyD88 signaling, but not of TLR4,
in zymosan-induced joint hypernociception in mice
In the ﬁrst series of experiments the participation of TLR2 and
TLR4, and adaptor molecule MyD88 in zymosan-induced joint hyper-
nociception was investigated using deﬁcient mice. Zymosan injected
in C57BL/6 WT mice induced a gradual lowering of the mechanical
joint ﬂexion, which was inhibited in TLR2−/− and MyD88−/− mice
(Fig. 1A). On contrary, joint administration of zymosan produced
hypernociception in C3H/HeJ (TLR4 signaling deﬁcient mice) mice
similar to observed in their littermates (C3H/HePas mice) (Fig. 1B).
These results suggest that TLR2/MyD88 signaling, but not TLR4, is in-
volved in hypernociceptive response induced by joint injection of zy-
mosan. As control, administration of LPS, a TLR4 agonist, into the joint
of C3H/HeJ mice did not induce hypernociception compared with
their littermates (C3H/HePas mice; data not shown in ﬁg.).
Fig. 1. Role of TLR2, TLR4 and MyD88 in zymosan-induced joint hypernociception.
Panel A) zymosan (Zym 30 μg/joint) or saline effect in C57BL/6 wild type (WT),
TLR2−/− and MyD88−/−. Panel B) Mechanical joint hypernociception was induced by
injection of Zym (30 μg/joint) in C3H/HePas and C3H/HeJ mice. Saline was used as a
control group. The intensity of hypernociception was evaluated by the mechanical
force applied to induce joint ﬂexion measured 1, 3, 5 and 7 h after zymosan tibio-
tarsal injection. The results are expressed as the mean±S.E.M. of ﬁve animals per
group. * means signiﬁcant difference compared with the saline group. # when com-
pared with zymosan injected group (Pb0.05).
Fig. 2. Participation of TNFα, IL-1β and CXCR1/2 ligands in zymosan-induced joint
hypernociception. Mechanical hypernociceptive response induced by joint injection
of Zymosan (30 μg/joint) was evaluated in C57BL/6 WT mice pretreated with vehicle,
IL-1ra (30 mg/kg, i.v.) and DF2162 (15 mg/kg, p.o) or in TNFR1−/−mice. The hyperno-
ciceptive responses were evaluated 1, 3, 5 and 7 h after zymosan intra-articular injec-
tion. The results are expressed by the mean±S.E.M. of ﬁve animals per group. The
symbol * means signiﬁcant difference compared with the saline injected group.
# when compared with the zymosan injected group treated with vehicle (Pb0.05).
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TNF-α, IL-1β and CXCL1/KC
To further investigate the mechanisms involved in the joint hyper-
nociceptive response induced by zymosan, we evaluated the partici-
pation of cytokines TNF-α and IL-β and chemokines (CXCR1/2
ligands, e.g. CXCL1/KC) in this response. C57BL/6 WT mice were pre-
treated with IL-1 receptor antagonist (IL-1ra, 30 mg/kg; i.v, 30 min
before zymosan injection, Cunha et al., 2008a; Verri et al., 2008) or
with CXCR1/2 antagonist (DF2162, 15 mg/kg; p.o., 60 min before zy-
mosan injection, Cunha et al., 2008b). Both treatments reduced joint
hypernociceptive response induced by zymosan (Fig. 2). To evaluate
the participation of TNFα, TNFR1−/− mice were used. Joint hyperno-
ciception induced by zymosan was also reduced in TNFR1−/− mice
compared with C57BL/6 WT mice (Fig. 2). Corroborating these re-
sults, joint administration of zymosan in C57BL/6 WT mice induced
a time-dependent production of TNFα, IL-1β and CXCL1/KC
(Fig. 3A–C). The levels of these cytokines were signiﬁcant elevated 3
and 5 h after zymosan injection (Fig. 3A–C). These results indicate
that TNFα, IL-1β and CXCL1/KC contribute to zymosan-induced joint
hypernociceptive response.
3.3. TLR2/MyD88 signaling is involved in cytokines production during
zymosan induced joint inﬂammation
In attempt to evaluate whether cytokines mediation of zymosan
induced joint hypernociception is triggered by the activation TLR2/
MyD88 signaling, the production of TNFα, IL-1β and CXCL1/KC were
evaluated in TLR2−/− and MyD88−/− mice after zymosan jointinjection. At 5 h after zymosan joint injection, the production of
TNFα, IL-1β and CXCL1/KC were reduced in TLR2−/− mice and they
were completely inhibited in MyD88−/− compared with the produc-
tion in C57BL/6 WT (Fig. 3A–C). These results suggest that TLR2/
MyD88 signaling triggers TNF-α, CXCL1/KC and IL-1β in the media-
tion of zymosan induced joint hypernociception.
3.4. Mechanisms involved in cytokine and chemokine mediation of
zymosan-induced joint hypernociception
Next, it was investigated the mechanisms involved in cytokine
mediation of zymosan-induced joint hypernociception. Firstly, the
role of TNF-α was investigated. Intra-articular injection of TNF-α in
C57BL/6 WT mice induced mechanical hypernociception in a dose-
and time-dependent manner (1–1000 pg/joint) (Fig. 4A). The maxi-
mum hypernociceptive response was observed with the dose of
100 pg of TNF-α. The hypernociception was already signiﬁcant 1 h
after TNF-α injection, reached a plateau at 5 h after injection, and
returned to control levels 24 h after injection (Fig. 4A). The joint
hypernociceptive effect of TNF-α was reduced by the pretreatment
of C57BL/6 WT mice with a non-selective inhibitor of cyclooxigenase
(indomethacin, 5 mg/kg, i.p. 30 min before TNF-α injection; Verri et
al., 2006) with a sympathomimetic neuron-blocking agent (guaneth-
idine, 30 mg/kg, s.c., 30 min before TNF-α injection; Pinto et al., 2010)
and it was inhibited by the association of indomethacin and guaneti-
dine (Fig. 4B). In addition, the pretreatment of C57BL/6 WT with IL-
1Ra (30 mg/kg, i.v., 30 min before TNF-α injection) and DF2162
(15 mg/kg, p.o., 60 min before TNF-α injection) also reduced TNF-α-
induced joint hypernociception (Fig. 4B). Conﬁrming these results,
the joint injection of TNF-α increased the production of CXCL-1/KC
(Fig. 4C) and IL-1β (Fig. 4D). The participation of TNF-α in the induc-
tion of CXCL-1/KC and IL-1β during zymosan-induced joint inﬂamma-
tion was conﬁrmed by the fact that the production of CXCL-1/KC and
IL-1β were reduced in TNFR1−/− mice (Fig. 4 C and D).
Next, the role of IL-1 β was evaluated. Intra-articular injection of
IL-1β induced joint hypernociception in a dose- and time-
dependent manner (100, 1000 and 5000 pg/joint) (Fig. 5A). The max-
imum hypernociceptive response was observed with the dose of
5000 pg of IL-1β. The hypernociception was already signiﬁcant 1 h
after IL-1β injection, reached a plateau at 5 h after articular injection
(Fig. 5A). The joint hypernociceptive effect of IL-1β was reduced by
the pretreatment of C57BL/6WTmice with indomethacin or guaneth-
idine, and it was inhibited by the association of indomethacin and
guanethidine (Fig. 5B). In addition, the pretreatment of C57BL/6 WT
with DF2162 also reduced IL-1β-induced joint hypernociception
Fig. 3. Articular injection of zymosan increases the production of TNF-α, IL-1β and
CXCL1/KC in joint tissue: role of TLR2/MyD88 signaling. Panel A: Concentration of
TNF-α in MyD88−/− and TLR2−/− deﬁcient mice and WT mice joint injected with of
zymosan or saline (Sal). At 5 h after intra-articular injection, mice were killed and
joint tissue samples were extracted for cytokines, which were measured by ELISA.
Panel B: Concentration of IL-1β in MyD88−/− and TLR2−/− deﬁcient mice and WT
mice joint injected with of zymosan or saline. At 5 h after intra-articular injection,
mice were killed and joint tissue samples were extracted for cytokines, which were
measured by ELISA. Panel C: Concentration of CXCL1/KC in MyD88−/− and TLR2−/−
mice and WT mice joint injected with zymosan or saline. At 5 h after intra-articular in-
jection, mice were killed and joint tissue samples were extracted for cytokines, which
were measured by ELISA. The results are expressed by the mean±S.E.M. of ﬁve ani-
mals per group. The symbol * means signiﬁcant difference when compared with the
saline group. # when compared with the zymosan injected inWTmice group (Pb0.05).
Fig. 4. TNF-α induced tibio-tarsal joint hypernociception. Panel A: Dose and time–
response curves of the hypernociception induced by intra-articular injection of TNF-
α (1, 10, 100 and 1000 pg/5 μl) or saline. The hypernociceptive effects were deter-
mined at 1, 3, 5, 7 and 24 h after intra-articular injection of TNF-α. Panel B: Nociceptive
response induced by TNF-α (100 pg/5 μl) WTmice pre-treatment with IL-1ra (30 mg/kg,
i.v.), DF2162 (15 mg/kg p.o., indomethacin (indo, 5 mg/kg i.pl.) guanethidine (GNT,
30 mg/kg s.c.) and indomethacin plus guanethidine. Panel C: Joint production of CXCL1/
KC in mice after intra-articular injection of TNF-α (100 pg/5 μl) and Zym (30 μg/5 μl) in
WT and in TNFR1−/− mice. Panel D: Joint production of IL-1β in mice after intra-
articular injection of TNF-α (100 pg/5 μl) and Zym (30 μg/5 μl) in WT and in TNFR1−/−
mice. The results are expressed by the mean±S.E.M. of ﬁve animals per group. The
symbol * means signiﬁcant difference when compared with the saline group. # when
compared with the zymosan injected in WT mice group (Pb0.05).
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was also reduced in TNFR1−/− mice (Fig. 5B). Further supporting
these results, joint injection of IL-1β increased the production of
TNF-α and CXCL1/KC in the joint of mice (Fig. 5C and D, respectively).
Moreover, the production of TNF-α and CXCL1/KC induced by zymo-
san joint injection was reduced by the treatment of mice with IL-1ra
(Fig. 5 C and D, respectively).
Finally, the role of CXCL-1/KC in the mediation of zymosan-
induced joint hypernociception was investigated. Intra-articularinjection of CXCL1/KC induced joint hypernociception in a dose- and
time-dependent manner (1–100 ng/joint; Fig. 6A). The maximum
hypernociceptive response was observed with the dose of 30 ng of
CXCL1/KC. The joint hypernociception was already signiﬁcant 1 h
after CXCL1/KC injection, reached a plateau at 5 h after joint injection
(Fig. 6A). The joint hypernociceptive effect of CXCL1/KC was reduced
by the pretreatment of C57BL/6 WT mice with indomethacin or gua-
nethidine, and it was inhibited by the association of indomethacin
and guanethidine (Fig. 6B). In addition, the pretreatment of C57BL/6
WT with IL-1ra also reduced CXCL1/KC-induced joint hypernocicep-
tion (Fig. 6B). Moreover, the joint hypernociceptive response induced
by CXCL1/KC was reduced in TNFR1−/− mice (Fig. 6B). In agreement,
joint injection of CXCL1/KC increased the production of IL-1β and
TNF-α (Fig. 6C and D, respectively). Moreover, zymosan induced the
production of TNF-α and CXCL1/KC in C57BL/6 WT which was re-
duced by the treatment with DF2162 (Fig. 6C and D, respectively)
4. Discussion
Arthritic pain is a serious health problem that affects a large num-
ber of patients. Therefore, the knowledge of the underlying mecha-
nisms involved in its genesis could lead to the development of novel
and effective pharmacological therapies. In the present study, we in-
vestigated the role of TLRs and their signaling in the cascade of events
that mediate arthritic nociception in zymosan-induced arthritis. We
Fig. 5. IL-1β induced tibio-tarsal joint hypernociception. Panel A: Dose and time–
response curves of the hypernociception induced by intra-articular injection of IL-1β
(100, 1000 and 5000 pg/5 μl) or saline. The hypernociceptive effects were determined
at 1, 3, 5, 7 and 24 h after intra-articular injection of IL-1β. Panel B: Nociceptive
response induced by IL-1β (5000 pg/5 μl) in TNFR1−/− mice or in WT mice pretreated
with DF2162 (15 mg/kg delivered p.o.) indomethacin (indo, 5 mg/kg delivered i.pl.)
guanethidine (GNT, 30 mg/kg delivered s.c.) and indomethacin plus guanethidine.
Panel C: Joint production of TNF-α in mice after intra-articular injection of IL-1β
(5000 pg/5 μl) and Zym (30 μg/5 μl) in vehicle an IL-1ra (30 mg/kg, i.v.) treated mice.
Panel D: Joint production of CXCL1/KC in mice after intra-articular injection of IL-1β
(5000 pg/5 μl) and Zym (30 μg/5 μl) in vehicle and IL-1ra treated mice. The results
are expressed by the mean±S.E.M. of ﬁve animals per group. The symbol * means sig-
niﬁcant difference when compared with the saline group. # when compared with the
IL-1ra treated group (Pb0.05).
Fig. 6. CXCL1/KC induced tibio-tarsal joint hypernociception. Panel A: Dose and time–
response curves of the hypernociception induced by intra-articular injection of CXCL1/
KC (1, 10 and 30 ng/5 μl) or saline. The hypernociceptive effects were determined at 1,
3, 5, 7 and 24 h after intra-articular injection of CXCL1/KC. Panel B: Nociceptive
response induced by CXCL1/KC (10 ng/5 μl) in TNFR1−/− mice and in WT mice pre-
treated with IL-1ra (30 mg/kg, i.v.), indomethacin (indo, 5 mg/kg i.pl.) guanethidine
(GNT, 30 mg/kg s.c.) and indomethacin plus guanethidine. Panel C: Joint production
of TNF-α in mice after intra-articular injection of CXCL1/KC (10 ng/5 μl), and Zym
(30 μg/5 μl) in vehicle and DF2162 (15 mg/kg, p.o.) treated mice. Panel D: Joint produc-
tion of IL-1β in mice after intra-articular injection of CXCL1/KC (10 ng/5 μl), and Zym
(30 μg/5 μl) in vehicle and DF2162 (15 mg/kg, p.o.) treated mice. The results are
expressed by the mean±S.E.M. of ﬁve animals per group. The symbol * means signiﬁ-
cant difference when compared with the saline group. # when compared with DF2162
treated group (Pb0.05).
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on activation of TLR2/MyD88, but not TLR4 signaling pathway, those
result in the production of cytokines (TNF-α, IL-1β and CXCL1/KC)
which acts in a reciprocal/self-stimulatory cytokine cascade. Probably
these cytokines lead to the production of prostanoids and sympathet-
ic amines that ultimately sensitize the primary nociceptive neurons as
observed in other models of inﬂammation (Cunha et al., 2005;
Guerrero et al., 2006).
There are previous evidences that TLR2 and TLR4 are functionally
expressed in synovial tissue of patients with rheumatoid arthritis and
their activation leads to the production of several inﬂammatorymedi-
ators (De Rycke et al., 2005; Iwahashi et al., 2004; Pierer et al., 2004;
Radstake et al., 2005). In this context, TLR2 and TLR4 deﬁcient mice
present reduced arthritis in a range of experimental models, either
in auto-immune or infections triggered arthritis (Joosten et al.,
2003; Liu-Bryan et al., 2005). The current hypothesis is that endoge-
nous produced or pathogen-derived molecules could activate synovi-
al TLRs participating in the physiopathology of those diseases
(Roelofs et al., 2005). Here, we extend these studies presenting evi-
dence that TLR2/MyD88 signaling, but not TLR4, is involved in the in-
duction of articular nociception in zymosan-induced arthritis. Our
result is in accordance with previous evidence showing that zymosan,
at least in vitro, directly activates TLR2 but not TLR4 (Lamkanﬁ et al.,2009). Besides to act as TLR2 agonist, zymosan might also stimulate
endogenous agonists of TLR2 receptors such as heat shock proteins
which could amplify the inﬂammatory process (Roelofs et al., 2005).
Although TLR4 did not participate in joint hypernociception during
zymosan-induced arthritis, it could contribute to pain in other models
of arthritis, including in LPS-induced joint inﬂammation and also in
humans. Moreover, it was recently showed that the activation of
TLR4 by an endogenous mediator play a critical role in the persistence
of synovial inﬂammation and tissue destruction in the chronic phase
of zymosan-induced arthritis (Midwood et al., 2009).
The hypernociceptive mechanisms triggered by the activation of
TLR2/MyD88 signaling during zymosan-induced arthritis seems to
be dependent on the stimulation of the production of pro-
nociceptive cytokines and chemokines, including TNF-α, IL-1β and
CXCL1, respectively. Previous studies have demonstrated that TLR-2/
MyD88 signaling lead to the activation of NF-κB (Andreakos et al.,
2005) in a mechanism dependent on MAP kinases (Takeda and
Akira, 2005). Our ﬁndings suggested that joint of TLR2−/− and
MyD88−/− mice injected with zymosan exhibited decrease levels in
the production of TNF-α, IL-1β and CXCL1/KC. It was interesting
that although the production of these cytokines was reduced in
TLR2−/−, the reductions were more pronounced in MyD88−/−, sug-
gesting that a mechanism other than activation of TLR2 might ac-
count for the stimulation of MyD88 pathway and the production of
cytokines (Joosten et al., 2003). Maybe the activation of other TLRs
Fig. 7. Representative diagram of the mechanism underling the TLR2 mediation of
hypernociception in zymosan-induced arthritis.The ﬁg. summarizes the essential con-
clusion of the present study, which shows the role of TLR2/MyD88 signaling in arthritic
pain by the stimulation of TNF-α, IL-1β and CXCL1/KC, which in turn promote the pro-
duction of prostaglandins and sympathetic amines (SA).
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dent events.
The production of TNF-α, IL-1β and CXCL8/IL-8 (counterpart of
mouse CXCL1/KC) in synovial tissue of patients with rheumatoid
arthritis appears to be an important process in the pathogenesis of
this auto-immune disease (Torres et al., 2009). Experimentally,
these cytokines and chemokines play a critical role in the manifesta-
tion of inﬂammatory hypernociception in vast number of experimen-
tal models (Cunha et al., 2005, 2008a, 2008b; Verri et al., 2006). For
instance, genetic or pharmacological inhibition of TNFR1, IL-1R1 and
CXCR2, the respective receptor for TNFα, IL-1β and CXCL1/KC
reduced articular hypernociception in a model antigen-induced
arthritis (Verri et al., 2008). In the present study, we further elucidate
the relationship among these cytokines in producing joint hypernoci-
ception. Although the group of cytokines that mediates paw
inﬂammation-induced hypernociception is the same detected in
zymosan-induced joint hypernociception, the mechanism operating
their action seems to be quite different. Indeed, differently from we
have demonstrated in the plantar hypernociception of rats and mice
in which inﬂammation induced the production of a sequential cas-
cade of pro-hypernociceptive cytokines (Cunha et al., 1992, 2005),
in the joint inﬂammation, it seems that these cytokines are released
in an interdependent manner, but not sequentially. These results
indicate that targeting 1 of these cytokines could break the cycle
and reduce joint hypernociception. It is obvious that these cyto-
kines/chemokines have other roles in joint tissue pathophysiology
of rheumatoid arthritis, and is up to us to determine the best target
with reduced side-effect incidence. One important fact is that
zymosan-induced hypernociception at earlier time point (1 h after)
seems to be not mediated by these cytokines. In fact, mediators
such as leukotriene B4 (Guerrero et al., 2008), platelet activating fac-
tor (Guerrero et al., unpublished results) and C5a (Ting et al., 2008)
might be involved in this zymosan effect.
It is important to point out that the hypernociceptive action of cy-
tokines in the joint, as observed in the paw (Cunha et al., 2005), is in-
directly, via the production of directly acting hypernociceptive
mediators such as prostaglandins and sympathetic amines. Nonethe-
less, there are evidences that cytokines could be acting directly on
primary nociceptive neurons promoting their sensitization (Richter
et al., 2010). The in vivo importance of directly or indirectly action
of cytokines for the induction of joint hypernociception still needs
to be demonstrated, for example, by the use of conditional mice
with deletion of cytokines receptors only in primary nociceptive
neurons.
Besides the involvement of local (joint) activation of TLR2 in the
induction of arthritis pain, there is recent data suggesting that the
chroniﬁcation of pain process, at least during neuropathic process
after peripheral nerve injury, depends on TLR2 expressed in the cen-
tral nerve system (Kim et al., 2007). It seems that there are molecules
released by injured neurons that activate TLR2 (Kim et al., 2007). Fur-
thermore, the stimulation of TLR2 in microglial cell promotes their
activation and contributes to the maintenance of neuropathic pain
(Kim et al., 2007). Therefore, it is plausible to suggest that the chron-
iﬁcation of pain in arthritis, in which microglia activation also plays a
role (Sun et al., 2007), could be dependent on spinal activation of
TLR2 signaling.
Our study presents an insight in the mechanisms that trigger
arthritic pain, demonstrating that the activation TLR2/MyD88 signal-
ing plays an important role. The TLR2/MyD88 signaling drives the
production of pronociceptive cytokines including TNF-α, IL-1β and
CXCL1/KC, which act in an interdependent manner, one releasing
each other. In the joint, the hypernociceptive effect of cytokines is
also indirect through the stimulation of directly sensitizing mediators
(prostanoids and sympathetic amines), which might sensitize prima-
ry nociceptive neurons leading to joint hypernociception (Fig. 7). This
process is in line with the explanation that in arthritis analgesia canbe achieved by the use of corticoids and selective inhibitor of cyto-
kines (human antibodies) that blockade the release/action of hyperal-
gesic cytokines and non steroid anti-inﬂammatory drugs (NSAID),
which prevent prostanoids-induced nociceptor sensitization. In
conclusion, the present results indicate that the development of in-
hibitors of TLR2/MyD88 or downstream (cytokines/chemokines) sig-
naling could be an alternative to control arthritic pain.
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